Brexucabtagene Autoleucel
‘Reassuring’ study shows no link between CAR T-cell therapy and secondary cancers
A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.
‘Wake-up call’: Cancer cachexia causes worse outcomes after CAR-T for lymphoma
Historically, Jae H. Park, MD, has not paid much attention to his patients’ weight loss.
Serious cardiovascular events rare after CAR T-cell therapy
A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.
Risk for second primary malignancies no greater with CAR-T than other standard therapies
Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.
FDA requires boxed safety warning for all CAR T-cell therapies
The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.
FDA official says CAR-T ‘incredibly beneficial’ despite secondary malignancy risk
Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.
FDA issues warning about risk of T-cell malignancies after CAR T-cell therapy
The FDA published a safety advisory on the risk of T-cell malignancies among individuals receiving autologous chimeric antigen receptor T-cell therapy for the treatment of certain blood cancers.
Tecartus CAR-T shows long-term durability among adults with advanced B-cell ALL
Brexucabtagene autoleucel continued to confer a greater than 70% complete remission rate among adults with relapsed or refractory B-cell acute lymphoblastic leukemia, results from the latest analysis of a pivotal phase 2 study showed.
FDA approves Tecartus for B-cell precursor ALL
The FDA approved brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
CAR T-cell therapy shows ‘high and durable response rates’ in adults with B-cell ALL
Brexucabtagene autoleucel induced an overall remission rate of greater than 70% among adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a single infusion of the therapy, according to phase 2 study results.